VERAXA Biotech Partners With Ardigen to Leverage AI in Cancer Drug Development

VERAXA Biotech AG (NASDAQ: VRXA) announced a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.

According to VERAXA, integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.

For more details, the full press release is available at https://ibn.fm/GLFg2.

VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

Investors can find the latest news and updates relating to VRXA in the company’s newsroom at http://ibn.fm/VRXA.

This collaboration highlights the growing trend of integrating AI into biopharmaceutical R&D to accelerate the development of more effective cancer therapies. By leveraging Ardigen's expertise in AI and bioinformatics, VERAXA aims to overcome historical challenges in oncology drug development, particularly the high failure rates due to toxicity. The partnership could set a precedent for how AI is used to de-risk drug development and improve patient outcomes.